Pro Medicus Ltd (OTCPK:PMCUF)
$ 115 5 (4.55%) Market Cap: 12.55 Bil Enterprise Value: 11.90 Bil PE Ratio: 218.22 PB Ratio: 95.83 GF Score: 92/100

Full Year 2024 Pro Medicus Ltd Earnings Call Transcript

Aug 14, 2024 / 01:00AM GMT
Release Date Price: $80.09

Key Points

Positve
  • Revenue increased by 29.3% and profit after tax rose by 36.5%, indicating strong financial performance.
  • Nine new contract wins in North America, all cloud-based, showcasing successful market penetration.
  • Continued investment in AI and other ologies, positioning the company for future growth.
  • Record year in terms of new sales and successful implementations, setting a strong base for FY25.
  • High client retention rate with 100% renewal, demonstrating customer satisfaction and loyalty.
Negative
  • Ongoing radiologist shortage and burnout issues, which could impact service delivery.
  • High dependency on the US market, which may pose risks if market conditions change.
  • Some delays in contract implementations, such as the Baylor Scott & White contract.
  • Increased operational costs, including a 26% rise in employee benefits, which could impact margins.
  • Challenges in penetrating the private radiology market due to price sensitivity.
Sam Hupert
Pro Medicus Ltd - Chief Executive Officer, Managing Director and Executive Director

Thank you. Good morning everybody and thanks for joining us for our full-year results presentation. As most of you know we're a healthcare IT company specializing in enterprise imaging and radiology informatics systems. We work in three jurisdictions: Melbourne, Australia, our corporate office and where we do the development and sales for our RIS product; Berlin which is our R&D center and one support center for the Visage product; and US which is our main market.

We are heavily technically focused. Nearly half our staff are either programmers or technical support. The second biggest group of staff are clinical support because as you know ours is a clinical product. So very much client-focused staff mix.

In terms of our results, we believe all of our key metrics moved in the right direction. Obviously, revenue was up 29.3%; and profit after tax, 36.5%. I think underlying EBIT was also up, as were our margins. And I think, pleasingly, we continued to accrue cash even after paying dividends

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot